{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:19:35Z","timestamp":1774628375144,"version":"3.50.1"},"reference-count":70,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"unspecified","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"publisher","award":["Clinician-Investigator Award"],"award-info":[{"award-number":["Clinician-Investigator Award"]}],"id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010369","name":"Green Templeton College, University of Oxford","doi-asserted-by":"publisher","award":["Clarendon Fund"],"award-info":[{"award-number":["Clarendon Fund"]}],"id":[{"id":"10.13039\/100010369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004713"],"award-info":[{"award-number":["INV-004713"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjph"],"accepted":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Visceral leishmaniasis (VL) is a neglected tropical disease prevalent in populations affected by poverty and poor nutrition. Without effective treatment, death is the norm. Prognostic models can steer clinical decision-making by identifying patients at high risk of adverse outcomes. We aimed to identify, summarise and critically appraise prognostic models predicting future clinical outcomes in patients with VL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed all studies that developed, evaluated or updated prognostic models predicting future clinical outcomes in patients diagnosed with VL. Five bibliographic databases (Ovid Embase, Ovid MEDLINE, Web of Science Core Collection, SciELO and LILACS) were searched from database inception to 1 March 2023, with an update to 18 December 2025. Screening, data extraction and risk of bias assessment (Prediction Model Risk of Bias Assessment Tool) were performed independently and in duplicate. Results are presented with tables, figures and a narrative synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight studies, published between 2003 and 2021, were identified describing 12 prognostic model developments. 10 models were evaluated in settings that were either geographically or temporally distinct from those used for model development, resulting in 19 external validations. All models predicted mortality, either using hospital-based cohorts (10 models) or registry data (2 models), and were developed in either Brazilian or East African populations (9 and 3 models, respectively). Model discrimination (c-statistics) ranged from 0.56 to 0.93\u2009when evaluated in the same patients used for model development (apparent performance, 12 models), and 0.62 to 0.92\u2009when evaluated in new settings (19 external validations, 10 models). All model developments and evaluations were judged at high risk of bias: no studies presented calibration plots, 11 models were at high risk of overfitting due to small sample sizes, and four models presented risk scores that did not correspond to the reported regression coefficients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All identified models predict mortality and were developed in Brazilian or East African patient populations. No prognostic models were identified that predict treatment failure or relapse, and despite South Asia accounting for the highest global VL burden prior to 2010, no models were developed in this population. Within the context of the ongoing elimination programmes in South Asia and East Africa, these represent important evidence gaps where new model development should be prioritised. Information presented in this review can be used by clinicians and policymakers to assess the applicability of existing models to their own patient settings. However, with a high risk of bias identified for all models, caution should be exercised when interpreting model risk and performance estimates. We direct interested readers to expert guidance to support transparent reporting and reduce common sources of bias in the development and evaluation of prediction models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023417226.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjph-2024-001196","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:45:20Z","timestamp":1774626320000},"page":"e001196","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review"],"prefix":"10.1136","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct05602610","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3615-4928","authenticated-orcid":false,"given":"James Patrick","family":"Wilson","sequence":"first","affiliation":[{"name":"Nuffield Department of Medicine, Infectious Diseases Data Observatory, University of Oxford, Oxford, UK"},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forhad","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Infectious Diseases Data Observatory, University of Oxford, Oxford, UK"},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shermarke","family":"Hassan","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Infectious Diseases Data Observatory, University of Oxford, Oxford, UK"},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-8959","authenticated-orcid":false,"given":"Elinor","family":"Harriss","sequence":"additional","affiliation":[{"name":"Bodleian Health Care Libraries, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Musa","sequence":"additional","affiliation":[{"name":"Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabin","family":"Dahal","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Infectious Diseases Data Observatory, University of Oxford, Oxford, UK"},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasia","family":"Stepniewska","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Infectious Diseases Data Observatory, University of Oxford, Oxford, UK"},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-2963","authenticated-orcid":false,"given":"Philippe J","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Infectious Diseases Data Observatory, University of Oxford, Oxford, UK"},{"name":"Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026032708450925000_4.1.e001196.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31204-2"},{"key":"2026032708450925000_4.1.e001196.2","unstructured":"World Health Organization . Leishmaniasis. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis [Accessed 24 Aug 2023]."},{"key":"2026032708450925000_4.1.e001196.3","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00048-18","article-title":"Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2026032708450925000_4.1.e001196.4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00061-07"},{"key":"2026032708450925000_4.1.e001196.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b375","article-title":"Prognosis and prognostic research: what, why, and how?","volume":"338","author":"Moons","year":"2009","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.6","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1377"},{"key":"2026032708450925000_4.1.e001196.7","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0698"},{"key":"2026032708450925000_4.1.e001196.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1328","article-title":"Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal","volume":"369","author":"Wynants","year":"2020","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044687","article-title":"Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults","volume":"11","author":"Peetluk","year":"2021","journal-title":"BMJ Open"},{"key":"2026032708450925000_4.1.e001196.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030793","article-title":"Prognostic models for the clinical management of malaria and its complications: a systematic review","volume":"9","author":"Njim","year":"2019","journal-title":"BMJ Open"},{"key":"2026032708450925000_4.1.e001196.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001381","article-title":"Prognosis Research Strategy (PROGRESS) 3: prognostic model research","volume":"10","author":"Steyerberg","year":"2013","journal-title":"PLoS Med"},{"key":"2026032708450925000_4.1.e001196.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178996","article-title":"Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia","volume":"12","author":"Abongomera","year":"2017","journal-title":"PLoS One"},{"key":"2026032708450925000_4.1.e001196.13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1590\/0037-8682-0258-2016","article-title":"Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software","volume":"49","author":"Costa","year":"2016","journal-title":"Rev Soc Bras Med Trop"},{"key":"2026032708450925000_4.1.e001196.14","unstructured":"Costa D . Fatores de progn\u00f3stico na leishmaniose visceral: altera\u00e7\u00f5es cl\u00ednicas e laboratoriais associadas \u00e0 resposta imune, aos dist\u00farbios da coagula\u00e7\u00e3o e \u00e0 morte. 2009."},{"key":"2026032708450925000_4.1.e001196.15","unstructured":"Ministry of Health (Brazil) . Visceral Leishmaniasis: Clinical Recommendations for Lethality Reduction (Leishmaniose Visceral: Recomenda\u00e7\u00f5es Cl\u00ednicas Para Redu\u00e7\u00e3o Da Letalidade. 1st edn. Brasilia, Brazil, 2011."},{"key":"2026032708450925000_4.1.e001196.16","unstructured":"Ministry of Health (Brazil) . Guide to Health Surveillance. 6th edn. Brasilia, Brazil, 2024."},{"key":"2026032708450925000_4.1.e001196.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000705","article-title":"Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends","volume":"4","author":"Gorski","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.18","doi-asserted-by":"publisher","DOI":"10.1086\/381203"},{"key":"2026032708450925000_4.1.e001196.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003374","article-title":"Prognostic factors and scoring system for death from visceral leishmaniasis: an historical cohort study in Brazil","volume":"8","author":"Coura-Vital","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s15010-003-3139-9","article-title":"Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil","volume":"31","author":"Werneck","year":"2003","journal-title":"Infection"},{"key":"2026032708450925000_4.1.e001196.21","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-40","article-title":"External validation of multivariable prediction models: a systematic review of methodological conduct and reporting","volume":"14","author":"Collins","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026032708450925000_4.1.e001196.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075597","article-title":"Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review","volume":"13","author":"Wilson","year":"2023","journal-title":"BMJ Open"},{"key":"2026032708450925000_4.1.e001196.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073538","article-title":"Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA)","volume":"381","author":"Snell","year":"2023","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"2026032708450925000_4.1.e001196.25","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1376"},{"key":"2026032708450925000_4.1.e001196.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i6460","article-title":"A guide to systematic review and meta-analysis of prediction model performance","volume":"356","author":"Debray","year":"2017","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.025"},{"key":"2026032708450925000_4.1.e001196.28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.29","doi-asserted-by":"publisher","DOI":"10.1136\/jamia.2001.0080391"},{"key":"2026032708450925000_4.1.e001196.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032844","article-title":"Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews","volume":"7","author":"Geersing","year":"2012","journal-title":"PLoS One"},{"key":"2026032708450925000_4.1.e001196.31","unstructured":"Covidence systematic review software, veritas health innovation, Melbourne, Australia."},{"key":"2026032708450925000_4.1.e001196.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2026032708450925000_4.1.e001196.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l737","article-title":"Guide to presenting clinical prediction models for use in clinical settings","volume":"365","author":"Bonnett","year":"2019","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001511","article-title":"Early clinical manifestations associated with death from visceral leishmaniasis","volume":"6","author":"de Ara\u00fajo","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000877","article-title":"Risk Factors for Death in Children with Visceral Leishmaniasis","volume":"4","author":"Sampaio","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005921","article-title":"A clinical severity scoring system for visceral leishmaniasis in immunocompetent patients in South Sudan","volume":"11","author":"K\u00e4mink","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.37","doi-asserted-by":"crossref","unstructured":"Foinquinos J , Duarte M do C , Figueiroa JN , et al . Temporal Validation of a Predictive Score for Death in Children with Visceral Leishmaniasis. J Trop Med 2021;6688444. doi:10.1155\/2021\/6688444","DOI":"10.1155\/2021\/6688444"},{"key":"2026032708450925000_4.1.e001196.38","doi-asserted-by":"crossref","first-page":"100453","DOI":"10.1016\/j.orhc.2024.100453","article-title":"Predicting leishmaniasis outbreaks in Brazil using machine learning models based on disease surveillance and meteorological data","volume":"44","author":"Donizette","year":"2025","journal-title":"Oper Res Health Care"},{"key":"2026032708450925000_4.1.e001196.39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.115.001693"},{"key":"2026032708450925000_4.1.e001196.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006164","article-title":"Changing demographics of visceral leishmaniasis in northeast Brazil: Lessons for the future","volume":"12","author":"Lima","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"2026032708450925000_4.1.e001196.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001221"},{"key":"2026032708450925000_4.1.e001196.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-023-02008-1","article-title":"Sample size requirements are not being considered in studies developing prediction models for binary outcomes: a systematic review","volume":"23","author":"Dhiman","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"2026032708450925000_4.1.e001196.45","doi-asserted-by":"crossref","unstructured":"Steyerberg EW . Overfitting and optimism in prediction models. In: Clinical Prediction Models. Cham: Springer International Publishing, 2019: 95\u2013112.","DOI":"10.1007\/978-3-030-16399-0_5"},{"key":"2026032708450925000_4.1.e001196.46","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078276","article-title":"Developing clinical prediction models: a step-by-step guide","volume":"386","author":"Efthimiou","year":"2024","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i2416","article-title":"Prediction models for cardiovascular disease risk in the general population: systematic review","volume":"353","author":"Damen","year":"2016","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l5358","article-title":"Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal","volume":"367","author":"Bellou","year":"2019","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.50","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074819","article-title":"Evaluation of clinical prediction models (part 1): from development to external validation","volume":"384","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.51","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074820","article-title":"Evaluation of clinical prediction models (part 2): how to undertake an external validation study","volume":"384","author":"Riley","year":"2024","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.52","doi-asserted-by":"crossref","unstructured":"Riley RD , Snell KIE , Archer L , et al . Evaluation of clinical prediction models (part 3): calculating the sample size required for an external validation study. BMJ 2024. doi:10.1136\/bmj-2023-074821","DOI":"10.1136\/bmj-2023-074821"},{"key":"2026032708450925000_4.1.e001196.53","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"2026032708450925000_4.1.e001196.54","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12070969","article-title":"From Infection to Death: An Overview of the Pathogenesis of Visceral Leishmaniasis","volume":"12","author":"Costa","year":"2023","journal-title":"Pathogens"},{"key":"2026032708450925000_4.1.e001196.55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008319","article-title":"Prognostic factors for mortality among patients with visceral leishmaniasis in East Africa: Systematic review and meta-analysis","volume":"14","author":"Abongomera","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002982","article-title":"Risk factors for adverse prognosis and death in American visceral leishmaniasis: a meta-analysis","volume":"8","author":"Belo","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.57","unstructured":"World Health Organization . Regional Strategic Framework for Accelerating and Sustaining Elimination of Kala-Azar in the South-East Asia Region, 2022-2026. New Delhi: World Health Organization, South-East Asian Region, 2022."},{"key":"2026032708450925000_4.1.e001196.58","unstructured":"Strategic Framework for the Elimination of Visceral Leishmaniasis as a Public Health Problem in Eastern Africa. 2023-2030. Geneva: World Health Organization, 2024."},{"key":"2026032708450925000_4.1.e001196.59","unstructured":"World Health Organization . Target product profile for a diagnostic test to confirm cure of visceral leishmaniasis. 2024. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240091818"},{"key":"2026032708450925000_4.1.e001196.60","unstructured":"Infectious Diseases Data Observatory . Development and validation of a prognostic model for visceral leishmaniasis relapse | infectious diseases data observatory. Available: https:\/\/www.iddo.org\/development-and-validation-prognostic-model-visceral-leishmaniasis-relapse [Accessed 24 Dec 2025]."},{"key":"2026032708450925000_4.1.e001196.61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001153","article-title":"Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review","volume":"5","author":"Cota","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.62","doi-asserted-by":"crossref","first-page":"21067","DOI":"10.1038\/s41598-025-07406-7","article-title":"AI-driven analysis by identifying risk factors of VL relapse in HIV co-infected patients","volume":"15","author":"Kumar","year":"2025","journal-title":"Sci Rep"},{"key":"2026032708450925000_4.1.e001196.63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2223\/JPED.652","article-title":"Predictive score of infectious complications on Kalazar of child","volume":"72","author":"J\u00fanior","year":"1996","journal-title":"J Pediatr (Rio J)"},{"key":"2026032708450925000_4.1.e001196.64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001542","article-title":"Predictive models for the diagnostic of human visceral leishmaniasis in Brazil","volume":"6","author":"Machado de Assis","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2026032708450925000_4.1.e001196.65","first-page":"535","article-title":"Visceral leishmaniasis in children: prognostic factors","volume":"81","author":"Abdelmoula","year":"2003","journal-title":"Tunis Med"},{"key":"2026032708450925000_4.1.e001196.66","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/cid\/ciab124","article-title":"Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa","volume":"73","author":"Verrest","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026032708450925000_4.1.e001196.67","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100487","article-title":"Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV","volume":"3","author":"Takele","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026032708450925000_4.1.e001196.68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/trstmh\/traa010","article-title":"Prognostic factors associated with death from visceral leishmaniasis: a case-control study in Brazil","volume":"114","author":"da Silva","year":"2020","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2026032708450925000_4.1.e001196.69","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jiph.2019.10.003","article-title":"Risk factors for in-hospital mortality from visceral leishmaniasis: A case-control study","volume":"13","author":"Oliveira-Sena","year":"2020","journal-title":"J Infect Public Health"},{"key":"2026032708450925000_4.1.e001196.70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-3156.2010.02694.x","article-title":"Risk factors for relapse of visceral leishmaniasis in Georgia","volume":"16","author":"Kajaia","year":"2011","journal-title":"Trop Med Int Health"}],"container-title":["BMJ Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjph-2024-001196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:45:29Z","timestamp":1774626329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpublichealth.bmj.com\/lookup\/doi\/10.1136\/bmjph-2024-001196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjph-2024-001196"],"URL":"https:\/\/doi.org\/10.1136\/bmjph-2024-001196","relation":{},"ISSN":["2753-4294"],"issn-type":[{"value":"2753-4294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}